cancer treatment

This morning an SSF Cell Therapy, currently on clinical trial, just laid off over 25%* of its employees. *Rumored quantity

In an exclusive interview with the AlphaStreet, ImmunoGen Inc (NASDAQ: IMGN) executive chief Mark Enyedy spoke about the company's product strategy, pipeline, and more. The pharma sector continues to be running on the tight budgets due to disruptive COVID-19 pandemic. However, ImmunoGen...

Eli Lilly is aggressively broadening its cancer portfolio by purchasing Loxo Oncology for $8 billion! Loxo shareholders are having a field day with 85% premium on share price. Despite the expensive deal value, the purchase is highly appreciated due to Loxo's hitherto success in cancer treatment...

In the past two weeks, Celgene has reported positive results from 3 clinical trials. This includes two studies with its partner Acceleron. https://news.alphastreet.com/celgene-gets-a-booster-shot-from-recent-positive-clinical-trial-results/

ARMO Biosciences loss in the fiscal year 2017 has increased compared to the fiscal year 2016. I don't know why Lilly is acquiring this loss making company. Will this acquisition really benefit Lilly? https://news.alphastreet.com/eli-lilly-acquires-armo-biosciences-strengthens-oncology-portfolio/

Celgene reported better-than-expected first quarter results, as its flagship drug for multiple myeloma continued to increase in new and repeat prescriptions and longer average duration of use. Revenue continued to be benefited from the company’s key growth driver Revlimid, which was approved...

Merck is hell-bent on becoming a major player in the lucrative immune-oncology space as its blockbuster cancer drug Keytruda met its goal of extending the lifespan of cancer patients. https://news.alphastreet.com/merck-sets-the-bar-high-for-rivals-with-positive-keytruda-trial-results/

http://alph.st/ba1df6ff Higher sales of Revlimid and Otezla help Celgene to report better than expected sales figure. Will the two (Impact and Juno) multi-billion dollar acquisitions help the struggling Celgene in 2018 and beyond?

It's an M&A Monday for the pharma companies. Two major pharma acquisitions announced today. 1) Celgene acquires Juno for $9 billion http://alph.st/pd7bf702 2) Sanofi acquires Bioverative for $11.6 billion Last week, there was a rumor that Celgene's acquisition of Juno and also news about...

Yesterday, WSJ has stated that Celgene is holding talks to acquire Juno Therapeutics. http://alph.st/pd7bf702 Will this move strengthen Celgene? In 2018, the first acquisition was Impact and now the unconfirmed Juno hunting.

Celgene strengthens its cancer portfolio by acquiring Impact Biomedicines. After stopping the Crohn's disease treatment trials and cutting down the 2020 outlook recently, this deal is a positive news for Celgene. But Sanofi had sold the rights of fedrantinib to Impact in 2016 when the drug was...

A trial testing Revlimid on follicular lymphoma did not meet the desired endpoint. Biogen's RITUXAN also fails..

Celgene announces positive results from the trials with its development partners Bluebird Bio and Juno Therapeutics in ASH 2017. I think it's an advantage for all the three companies involved; especially for Bluebird Bio.

http://alph.st/b9f74234 Remember, Celgene settled a lawsuit for the fraudulent use of Thalomid in July 2017 for $280 million. Now Lannett is going to manufacture the generic version of Thalomid.

Lilly signs a deal with Germany-based Curevac to strengthen its oncology division. http://alph.st/b72eaf5f

Verzenio fails in advanced lung cancer treatment, but advances in breast cancer treatment

Eli Lilly announces results of the Phase 3 JUNIPER trial study for Verzenio. Lilly gets a setback.

Verzenio fails and Levi Garraway says the outcome is unfortunate.

Lilly wins Alimta patent challenge. Also, Lilly had won Alimta patent battle against Actavis in July 2017.

FDA says okay to Eli Lilly's breast cancer drug Verzenio.